Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs 25:2, pages 145-158.
Read now
Read now
Carla Francés Artigas, Victoria Stokes, Garry D Tan & Michael J Theodorakis. (2015) Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice. Expert Opinion on Pharmacotherapy 16:10, pages 1417-1421.
Read now
Read now
Irl B. Hirsch, Doron Schneider, Aaron King, William H. Polonsky, Timothy S. Reid, Jay Shubrook, Carol A. Verderese, Jeffrey Wallace & Matthew C. Riddle. (2014) A Short-Acting GLP-1 Analog or Prandial Insulin to Supplement Basal Insulin?—Moving Toward Personalized Management of Type 2 Diabetes Mellitus. Postgraduate Medicine 126:3, pages 135-144.
Read now
Read now
Ronnie Aronson. (2013) Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus. Expert Review of Clinical Pharmacology 6:6, pages 603-612.
Read now
Read now
Articles from other publishers (7)
Yanwei Li, Lin Li & Christian Hölscher. (2016) Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Reviews in the Neurosciences 27:7, pages 689-711.
Crossref
Crossref
Johan Jendle, Marcia A. Testa, Sherry Martin, Honghua Jiang & Zvonko Milicevic. (2016) Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy. Diabetes, Obesity and Metabolism 18:10, pages 999-1005.
Crossref
Crossref
Tina Vilsbøll, Jiten Vora, Henrik Jarlov, Kajsa Kvist & Lawrence Blonde. (2016) Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Clinical Drug Investigation 36:4, pages 293-303.
Crossref
Crossref
Stephen C L Gough, Bruce Bode, Vincent Woo, Helena W Rodbard, Sultan Linjawi, Pernille Poulsen, Lars H Damgaard & John B Buse. (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. The Lancet Diabetes & Endocrinology 2:11, pages 885-893.
Crossref
Crossref
R. F. Arakaki, T. C. Blevins, J. K. Wise, D. R. Liljenquist, H. H. Jiang, J. G. Jacobson, S. A. Martin & J. A. Jackson. (2013) Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open‐label trial. Diabetes, Obesity and Metabolism 16:6, pages 510-518.
Crossref
Crossref
I. B. Hirsch, J. B. Buse, J. Leahy, J. B. McGill, A. Peters, H. W. Rodbard, R. R. Rubin, J. S. Skyler, C. A. Verderese & M. C. Riddle. (2014) Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, Obesity and Metabolism 16:3, pages 206-214.
Crossref
Crossref
B.H.R. Wolffenbuttel & M.M. van der Klauw. (2015) De nieuwe ADA/EASD-consensus type 2 diabetes en wat u daarvan moet weten. Nederlands Tijdschrift voor Diabetologie 10:4, pages 206-216.
Crossref
Crossref